+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evaluation of late cardiac toxicity of anthracycline in childhood

Evaluation of late cardiac toxicity of anthracycline in childhood

Minerva Pediatrica 50(4): 111-119

To examine left ventricular function in patients previously treated with anthracycline for childhood malignancies. To evaluate the importance of age at the beginning of therapy, of total cumulative dose and of length of follow-up on late cardiac effects of anthracyclines. Cross sectional echocardiography study of left ventricular function. Eighteen patients surviving between 1 and 9 years (median 2 years) from end of chemotherapy. Cumulative doses were between 120 and 550 mg/mq (median 275 mg/mq). Age at the beginning of chemotherapy was between 1.8 and 12.25 years (median 5.17 years). Nineteen healthy subjects were also studied as control group. Assessment of transmitral diastolic pulsed wave Doppler flow patterns and of transaortic pulsed wave Doppler flow patterns. Evaluation of systolic function measured by M-mode echocardiography. Patients compared to controls showed a significative reduction of Ejection Fraction, of Shortening Fraction, of peak early phase to peak atrial phase filling velocity ratio and an increase of peak atrial phase filling velocity and of time-velocity integral of peak filling atrial phase. These alterations were more evident at doses higher than 250 mg/m2, in patients whose therapy started before 5 years of age and in patients whose follow-up was longer than 5 years. Significant abnormalities of systolic and diastolic function may appear some years after the end of anthracycline therapy for childhood malignancies. Therefore patient's continued follow-up is necessary in order to guide patient care and to better chemotherapeutic protocols.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 046010881

Download citation: RISBibTeXText

PMID: 9808963

Related references

Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. Journal of Clinical Oncology 25(24): 3635-3643, 2007

Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25(7): 676-688, 2000

Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors. Journal of Pediatric Hematology/Oncology 32(5): 411-415, 2010

Late cardiac effects of anthracycline containing therapy for childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer 48(7): 663-667, 2007

Late cardiac damage of anthracycline therapy for acute lymphoblastic leukemia in childhood. Pediatric Hematology & Oncology 17(7): 527-540, October-November, 2000

Assessment of late anthracycline-induced cardiotoxicity by 123 I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence. Journal of Nuclear Cardiology 24(1): 256-264, 2017

Late cardiac effects of anthracycline therapy for childhood cancer Left ventricular systolic dysfunction in asymptomatic patients. European Heart Journal 16(ABSTR Suppl. ): 509, 1995

Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatric Research 39(3): 504-512, 1996

Early and late anthracycline-induced cardiotoxicity in childhood: non-invasive evaluation of contractility in 116 patients. Giornale Italiano di Cardiologia 25(10): 1295-1305, 1995

Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatric Blood and Cancer 44(4): 370-377, 2005

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. Journal of Cancer Survivorship 8(2): 183-189, 2014

Low-dose dobutamine echo stress test for the evaluation of cardiac function in asymptomatic childhood cancer survivors treated years before with anthracycline. European Heart Journal 19(ABST Suppl. ): 312, 1998

Evaluation of cardiac reserved function by high-dose dobutamine-stress echocardiography in asymptomatic anthracycline-treated survivors of childhood cancer. Pediatrics International 48(3): 313-320, 2006

Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?. Pediatric Hematology and Oncology 31(3): 237-252, 2014

The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up. Pediatric Hematology and Oncology 28(5): 380-394, 2011